pregabalin with chymotrypsin
Reading File
Finding Sources
Finding Sources
Searching the Web
pregabalin chymotrypsin combination tablet clinical use indications
Finding Sources
Searching the Web
pregabalin chymotrypsin fixed dose combination India anti-inflammatory neuropathic pain
Finding Sources
Reading File
Searching the Web
chymotrypsin trypsin serratiopeptidase enzyme tablet anti-inflammatory mechanism post-operative swelling
Reading Web Page
https://pmc.ncbi.nlm.nih.gov/articles/PMC5778189
Searching PubMed
pregabalin chymotrypsin combination neuropathic pain
Now I have enough information to provide a thorough answer on the combination of pregabalin and chymotrypsin.
Pregabalin + Chymotrypsin (Fixed-Dose Combination)
This is a fixed-dose combination (FDC) popular in India and other South Asian markets. The two drugs address different aspects of pain and inflammation, making their combination rational for conditions with both a neuropathic and a tissue-inflammatory component.
Individual Components
Pregabalin
| Property | Detail |
|---|---|
| Class | Gabapentinoid; GABA analog (but does NOT act on GABA receptors) |
| Mechanism | Binds to the α2-δ subunit of voltage-gated calcium channels in dorsal horn neurons → reduces release of excitatory neurotransmitters (glutamate, substance P, norepinephrine) → central pain modulation |
| Pharmacokinetics | Rapid oral absorption, NOT protein bound, minimal hepatic metabolism, ~95% excreted unchanged in urine, t½ ~6 hours; no significant drug-drug interactions via CYP enzymes |
| Indications | Diabetic peripheral neuropathy, postherpetic neuralgia, fibromyalgia, spinal cord injury pain, partial-onset seizures, generalized anxiety disorder |
| Dose range | 75-300 mg/day (in 2-3 divided doses) |
| Side effects | Dizziness, sedation, dry mouth, peripheral edema, weight gain |
(Bradley and Daroff's Neurology in Clinical Practice)
Chymotrypsin (Oral Proteolytic Enzyme)
Often combined with trypsin (as trypsin:chymotrypsin) in tablet form.
| Property | Detail |
|---|---|
| Class | Serine protease (proteolytic enzyme) |
| Mechanism | Hydrolyzes proteins and peptides at sites of inflammation and injury → breaks down necrotic tissue and inflammatory exudates → reduces edema and tissue destruction; enhances microcirculation; maintains α1-antitrypsin levels; augments phagocytic activity of NK cells and macrophages; antioxidant and fibrinolytic activity |
| Properties | Anti-inflammatory, anti-edematous, fibrinolytic, antioxidant, analgesic, anti-infective |
| Indications | Post-traumatic/post-surgical swelling and pain, soft tissue injuries, musculoskeletal disorders (tendinitis, bursitis, arthritis), wound healing |
| Dose | 1-2 tablets orally after food, as directed |
| Side effects | GI discomfort; rarely allergic reactions |
(PMC5778189 - Trypsin:Chymotrypsin in Tissue Repair)
Rationale for the Combination
The combination targets pain through two distinct and complementary pathways:
- Pregabalin - addresses the central/neuropathic component: modulates central sensitization, reduces hyperalgesia and allodynia by dampening spinal cord excitatory neurotransmission.
- Chymotrypsin - addresses the peripheral/inflammatory component: reduces local edema, inflammatory exudate, and tissue damage at the injury site, thereby reducing the nociceptive input that drives or sustains pain.
This dual mechanism is why the combination is especially useful in conditions where both nerve sensitization and tissue inflammation coexist.
Clinical Use Cases
- Post-operative pain management - particularly after orthopedic, dental, or spinal surgeries
- Musculoskeletal pain with nerve involvement - e.g., cervical or lumbar disc disease causing radiculopathy plus local soft tissue swelling
- Diabetic peripheral neuropathy with associated tissue inflammation
- Post-traumatic conditions involving both nerve injury and soft tissue damage
- Adjunct in multimodal analgesia to reduce opioid consumption
Pharmacokinetic Interactions
There are no known significant pharmacokinetic interactions between pregabalin and chymotrypsin. Pregabalin lacks hepatic CYP-mediated metabolism, so enzyme induction/inhibition is not a concern. The main caution for chymotrypsin (especially when combined with trypsin) is use alongside anticoagulants (warfarin, aspirin) - the proteolytic/fibrinolytic activity may potentiate bleeding risk.
Common FDC Products (Indian Market)
Brands like Pregastat-C, Chymoral Forte + Pregabalin, and similar combinations pair pregabalin (typically 75 mg) with chymotrypsin (or trypsin-chymotrypsin) to treat neuropathic pain with an inflammatory component. These are primarily marketed as anti-inflammatory + neuropathic pain combinations.
Note: No formal randomized clinical trials were found on PubMed specifically evaluating this pregabalin + chymotrypsin FDC, so clinical evidence for the specific combination is largely pharmacological rationale and observational/marketing data rather than high-quality RCT evidence. Each component individually has good evidence for its own indicated uses.
This is a shared conversation. Sign in to Orris to start your own chat.